Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC
September 29th 2014, 5:38am
Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.
CLEOPATRA Trial Update Shows Dramatic OS Benefit
September 28th 2014, 12:59pm
Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy for the treatment of HER2-positive metastatic breast cancer improved median OS by almost 16 months over standard first-line therapy.
Dr. Swain Discusses the Final OS Analysis from the CLEOPATRA Study
September 28th 2014, 12:53pm
Sandra M. Swain, MD, discusses final overall survival analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
Cediranib Combined With Chemotherapy Improves PFS in Advanced Cervical Cancer
September 28th 2014, 10:15am
Cediranib improved response rate and median PFS when added to conventional chemotherapy in a phase II study of patients with relapsed or metastatic cervical cancer.
Pembrolizumab Yields Durable Responses in Advanced NSCLC
September 28th 2014, 9:56am
Almost 60% of patients with advanced non–small cell lung cancer experienced tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.
Vintafolide Added to Docetaxel Improves Survival in Folate Receptor-Positive NSCLC
September 28th 2014, 8:08am
Vintafolide in combination with docetaxel showed improvements in PFS and OS compared with single-agent docetaxel as second-line treatment of patients with folate receptor–positive NSCLC.
Dr. Kluger on a Phase I Trial of Concurrent Nivolumab and Ipilimumab
September 28th 2014, 7:29am
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.
Anamorelin Improves Appetite, Slows Weight Loss in Lung Cancer
September 27th 2014, 10:42am
Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with the ghrelin agonist anamorelin.
Afatinib Improves PFS and Quality of Life in Advanced HNSCC
September 27th 2014, 7:46am
Afatinib delayed disease progression for approximately one month longer than chemotherapy and helped prevent painful symptoms from worsening for patients with relapsed or metastatic head and neck squamous cell carcinoma.
Dovitinib Meets Primary Endpoint in Phase II Trial of Advanced GIST
September 27th 2014, 7:32am
Dovitinib, an investigational oral tyrosine kinase inhibitor (TKI), demonstrated a "manageable" safety profile while controlling disease in about half of patients with advanced gastrointestinal stromal tumor (GIST) who had discontinued treatment with imatinib due to disease progression or intolerance
Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLC
September 27th 2014, 7:18am
Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.
Dr. Petrylak on the Results of the Phase II STRIDE Study
September 27th 2014, 6:24am
Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.
Bevacizumab Improves Survival in Metastatic Breast Cancer
September 25th 2014, 10:42am
Treatment with the combination of bevacizumab and chemotherapy improved PFS and OS in women with HER2-negative metastatic breast cancer.
Blood-Based Biomarkers Predict Outcomes Following Neoadjuvant Treatment in Esophageal Cancer
September 16th 2014, 4:14pm
High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Aggressive Treatment Leads to Long-Term Survival in Low-Risk Stage IV NSCLC
September 16th 2014, 2:30pm
Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival rate of patients with stage IV NSCLC.
Potentially Curative Surgery Achievable With Chemo/SABR Combination for Advanced Pancreatic Cancer
September 16th 2014, 2:11pm
The combination of chemotherapy and stereotactic ablative radiotherapy (SABR) may allow patients with locally advanced pancreatic cancer to undergo surgery, a procedure that might not have otherwise been an option
Vessel-Sparing Radiation Preserves Sexual Function in Men With Prostate Cancer
September 16th 2014, 2:08pm
With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option
Abbreviated Course of ADT + Radiation Improves QoL in High-Risk Prostate Cancer
September 16th 2014, 2:03pm
When given along with radiation therapy to men with high-risk prostate cancer, 18 months of androgen-deprivation therapy (ADT)-as opposed to a 36-month course-not only generates similar long-term outcomes, but results in a better quality of life
Radiotherapy Without Chemo Can Ease Dysphagia in Patients With Advanced Esophageal Cancer
September 15th 2014, 1:00pm
Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer
Radiation Therapy Improves Survival in Hodgkin's Lymphoma
September 15th 2014, 9:39am
Despite a recent decline in utilization, consolidated radiation therapy has been shown to improve 10-year survival rates for patients with stage I/II Hodgkin's lymphoma following treatment with chemotherapy